Is Integ. Proteins overvalued or undervalued?

Valuation Metrics Indicate Attractive Pricing

At a price of ₹38.25, Integ. Proteins trades with a price-to-earnings (PE) ratio of 42.6, which might appear elevated at first glance. However, this figure must be contextualised within the company’s broader valuation framework. The price-to-book (P/B) ratio stands at a notably low 0.69, suggesting the stock is trading below its book value, a classic indicator of undervaluation in asset terms.

Further, the enterprise value (EV) multiples provide additional insight. The EV to EBIT and EV to EBITDA ratios both hover around 14.06, which is moderate relative to industry standards. More strikingly, the EV to sales ratio is just 0.55, indicating the market values the company at just over half its annual sales, a conservative valuation metric.

The PEG ratio, which adjusts the PE ratio for earnings growth, is exceptionally low at 0.11. This implies that the stock’s price is low relative to its expected earnings growth, a strong signal that the market may be undervaluing the company’s growth prospects.

Peer Comparison Supports Attractive Valuation

When compared with peers in the edible oil industry, Integ. Proteins stands out as attractively valued. While some competitors like Manorama Industries and Raj Oil Mills are tagged as expensive with higher EV/EBITDA multiples, Integ. Proteins maintains a more reasonable multiple. Notably, Modi Naturals and M K Proteins are rated very attractive but trade at lower PE ratios, reflecting different growth or risk profiles.

Integ. Proteins’ valuation metrics are balanced between growth and value, with a PE ratio higher than some peers but supported by low EV to sales and PEG ratios. This suggests the market recognises growth potential but prices the stock conservatively, possibly due to recent performance volatility or sector-specific risks.

Financial Performance and Returns: A Mixed Picture

Despite the attractive valuation, the company’s return metrics raise some caution. The latest return on capital employed (ROCE) is a modest 1.18%, and return on equity (ROE) is similarly low at 1.62%. These figures indicate limited profitability relative to capital invested, which may explain the market’s cautious stance.

Looking at stock performance, Integ. Proteins has experienced significant volatility. Year-to-date and one-year returns are deeply negative, at -49.13% and -42.91% respectively, underperforming the Sensex benchmark which has delivered positive returns over the same periods. However, over a longer horizon, the stock has outperformed substantially, with a three-year return of 97.78% and an extraordinary ten-year return exceeding 1500%, reflecting strong long-term growth potential.

Market Price Context and Risk Considerations

The current share price of ₹38.25 is closer to the 52-week low of ₹20.71 than the high of ₹78.28, indicating the stock is trading well below its recent peak. This price compression could be due to sector headwinds or company-specific challenges, but it also presents a potential entry point for value investors.

It is important to note that the company does not currently pay dividends, which may deter income-focused investors. Additionally, the low profitability ratios suggest operational improvements are needed to justify higher valuations sustainably.

Conclusion: Undervalued with Caveats

Integ. Proteins currently appears undervalued based on several key metrics, including a low price-to-book ratio, modest EV to sales, and an exceptionally low PEG ratio. These factors suggest the market is pricing in significant growth potential at a discount. However, the company’s low profitability ratios and recent negative returns highlight operational challenges and risks that investors must consider.

For investors with a long-term horizon and a tolerance for volatility, Integ. Proteins offers an attractive entry point in the edible oil sector. The stock’s valuation metrics and historical outperformance indicate potential upside, provided the company can improve its returns on capital and navigate sector headwinds effectively.

In summary, while not without risk, Integ. Proteins is better characterised as undervalued rather than overvalued at present, making it a compelling candidate for value-oriented portfolios seeking exposure to the edible oil industry.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →